These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

57 related articles for article (PubMed ID: 19051500)

  • 1. Initial clinical study of tris(2,2-dimethyl-1-aziridinyl)phosphine oxide (TEPA-132).
    Mittelman A; Plager J; Murphy GP
    Cancer Chemother Rep; 1972 Jun; 56(3):393-9. PubMed ID: 19051500
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tris(l-aziridinyl)phosphine oxide (TEPA).
    DUVALL LR
    Cancer Chemother Rep; 1960 Jul; 8():156-75. PubMed ID: 13818928
    [No Abstract]   [Full Text] [Related]  

  • 3. Preparation and antitumor activity of tris(2,3-dimethyl-1-aziridinyl)phosphine oxide (TEPA-132).
    Munson AE; Babbitt HL; Chmielewicz ZF; Segaloff A; Bardos TJ; Ambrus JL
    Cancer Chemother Rep; 1967 Sep; 51(5):253-9. PubMed ID: 6075137
    [No Abstract]   [Full Text] [Related]  

  • 4. Cytogenetic and other effects of the chemosterilants tepa, metepa, apholate an hempa in insects (a review).
    Labrecque GC; Fye RL
    Mutat Res; 1978; 47(2):99-113. PubMed ID: 75501
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Thiono compounds. 4. In vitro mutagenic and antineoplastic activity of TEPA and thio-TEPA.
    Breau AP; Field L; Mitchell WM
    Cell Biol Toxicol; 1984 Oct; 1(1):21-30. PubMed ID: 6086064
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The preparation of 2,6-disubstituted pyridinyl phosphine oxides as novel anti-cancer agents.
    Lam KH; Gambari R; Yuen MC; Kan CW; Chan P; Xu L; Tang W; Chui CH; Cheng GY; Wong RS; Lau FY; Tong CS; Chan AK; Lai PB; Kok SH; Cheng CH; Chan AS; Tang JC
    Bioorg Med Chem Lett; 2009 Apr; 19(8):2266-9. PubMed ID: 19321340
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I/pharmacokinetic reevaluation of thioTEPA.
    O'Dwyer PJ; LaCreta F; Engstrom PF; Peter R; Tartaglia L; Cole D; Litwin S; DeVito J; Poplack D; DeLap RJ
    Cancer Res; 1991 Jun; 51(12):3171-6. PubMed ID: 1710167
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I clinical and pharmacological study of merbarone.
    Dimaggio JJ; Warrell RP; Muindi J; Stevens YW; Lee SJ; Lowenthal DA; Haines I; Walsh TD; Baltzer L; Yaldaei S
    Cancer Res; 1990 Feb; 50(4):1151-5. PubMed ID: 2297763
    [TBL] [Abstract][Full Text] [Related]  

  • 9. NTP Toxicology and Carcinogenesis Studies of Dimethyl Methylphosphonate (CAS No. 756-79-6) in F344/N Rats and B6C3F1 Mice (Gavage Studies).
    National Toxicology Program
    Natl Toxicol Program Tech Rep Ser; 1987 Nov; 323():1-172. PubMed ID: 12748730
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [CONTRIBUTION TO THE CHEMICAL AND PHARMACOLOGICAL STUDY OF AZIRIDINYL PHOSPHINE OXIDES].
    CHABRIER P; CHEYMOL G; NGUYENTHANH THUONG ; RIOULT P
    C R Seances Soc Biol Fil; 1964; 158():2057-9. PubMed ID: 14282110
    [No Abstract]   [Full Text] [Related]  

  • 11. Phase I study of 5-azacytidine (NSC-102816) .
    Weiss AJ; Stambaugh JE; Mastrangelo MJ; Laucius JF; Bellet RE
    Cancer Chemother Rep; 1972 Jun; 56(3):413-9. PubMed ID: 19051503
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I clinical and pharmacokinetic study of carzelesin (U-80244) given daily for five consecutive days.
    Wolff I; Bench K; Beijnen JH; Bruntsch U; Cavalli F; de Jong J; Groot Y; van Tellingen O; Wanders J; Sessa C
    Clin Cancer Res; 1996 Oct; 2(10):1717-23. PubMed ID: 9816122
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I trial of methotrexate-albumin in a weekly intravenous bolus regimen in cancer patients. Phase I Study Group of the Association for Medical Oncology of the German Cancer Society.
    Hartung G; Stehle G; Sinn H; Wunder A; Schrenk HH; Heeger S; Kränzle M; Edler L; Frei E; Fiebig HH; Heene DL; Maier-Borst W; Queisser W
    Clin Cancer Res; 1999 Apr; 5(4):753-9. PubMed ID: 10213209
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I trial of dihydroxyanthracenedione.
    Van Echo DA; Whitacre MY; Aisner J; Wiernik PH
    Cancer Treat Rep; 1981; 65(9-10):831-4. PubMed ID: 7273015
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prospective, randomized trial of sequential interleukin-3 and granulocyte- or granulocyte-macrophage colony-stimulating factor after standard-dose chemotherapy in cancer patients.
    Palmeri S; Leonardi V; Danova M; Porta C; Ferrari S; Fincato G; Citarrella P
    Haematologica; 1999 Nov; 84(11):1016-23. PubMed ID: 10553163
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I study of thiotepa in combination with the glutathione transferase inhibitor ethacrynic acid.
    O'Dwyer PJ; LaCreta F; Nash S; Tinsley PW; Schilder R; Clapper ML; Tew KD; Panting L; Litwin S; Comis RL
    Cancer Res; 1991 Nov; 51(22):6059-65. PubMed ID: 1933869
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I study of triglycidylurazol given on a 5-day i.v. schedule.
    Nicaise C; Rozencweig M; Crespeigne N; Dodion P; Gerard B; Lambert M; Decoster G; Kenis Y
    Cancer Treat Rep; 1986 May; 70(5):599-603. PubMed ID: 3708609
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ICON 2 and ICON 3 data in previously untreated ovarian cancer: results to date.
    Harper P
    Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-23-S15-25. PubMed ID: 9346217
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I and pharmacokinetic study of triapine, a potent ribonucleotide reductase inhibitor, administered daily for five days in patients with advanced solid tumors.
    Murren J; Modiano M; Clairmont C; Lambert P; Savaraj N; Doyle T; Sznol M
    Clin Cancer Res; 2003 Sep; 9(11):4092-100. PubMed ID: 14519631
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prospects of radioimmunotherapy in epithelial ovarian cancer: results with iodine-131-labeled murine and humanized MN-14 anti-carcinoembryonic antigen monoclonal antibodies.
    Juweid M; Swayne LC; Sharkey RM; Dunn R; Rubin AD; Herskovic T; Goldenberg DM
    Gynecol Oncol; 1997 Dec; 67(3):259-71. PubMed ID: 9441773
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.